Abstract:Sodium-dependent ascorbic acid membrane transporters SLC23A1 and SLC23A2 mediate ascorbic acid (vitamin C) transport into cells. However, it is unknown how ascorbic acid undergoes cellular release, or efflux. We hypothesized that SLC23A1 and SLC23A2 could serve a dual role, mediating ascorbic acid cellular efflux as well as uptake. Renal reabsorption is required for maintaining systemic vitamin C concentrations. Because efflux from nephron cells is necessary for reabsorption, we studied whether SLC23A1 and SLC… Show more
“…The kidney has a unique distribution of sodium-dependent vitamin C transporters (SVCT1 and SVCT2). SVCT1 is situated in the brush-border membrane of proximal tubule cells where it is responsible for maintaining whole body ascorbate levels by mediating renal reabsorption, whereas SVCT2 is expressed basolaterally in all cells in the kidney except the proximal tubule ( 30 – 32 ). Both papillary and clear cell RCC are presumed to derive from the epithelium of the proximal tubule which only expresses SVCT1 ( 33 ).…”
Hypoxia-inducible transcription factors (HIFs) drive angiogenesis and cancer cell growth, contributing to an aggressive tumor phenotype. HIF-α protein levels and activity are controlled at the post-translational level by HIF hydroxylases. Hydroxylated HIF-α is recognized by the von Hippel Lindau (VHL) tumor suppressor and targeted for degradation. The HIF hydroxylases are members of the iron and 2-oxoglutarate-dependent dioxygenases, which require ascorbate as cofactor for activity. Clear cell renal cell carcinomas (ccRCC) harbor mutations in the VHL gene, whereas papillary RCC (pRCC) have a functional VHL. These natural occurring VHL variants in RCC enable the testing, in clinical samples, of the hypothesis that ascorbate modulates HIF-α levels through its role as a cofactor for the HIF hydroxylases. We measured ascorbate, HIF-1α, and HIF-2α protein and HIF downstream targets BNIP3, CA9, cyclin D1, GLUT1, and VEGF (combined to generate the HIF pathway score) in VHL-defective ccRCC (n = 73) and VHL-proficient pRCC human tumor tissue (n = 41). HIF and ascorbate levels were increased in ccRCC and pRCC tumors compared to matched renal cortex. HIF-1 and total HIF pathway activation scores were decreased with higher ascorbate in pRCC tumors (Spearman r = −0.38, p < 0.05 and r = −0.35, p < 0.05). This was not evident for ccRCC tumors. In mechanistic studies in vitro, ascorbate influenced HIF-1 activity in VHL-proficient, but not VHL-defective ccRCC cells. Our results indicate that ccRCC, which lacks a functional VHL, does not respond to ascorbate-mediated modulation of the HIF response. This contrasts with the demonstrated association between ascorbate content and the HIF pathway observed in pRCC and other tumors with a functional VHL. The results support a role for ascorbate as a modulator of HIF activity and tumor aggression in cancer types with a functional hypoxic response.
“…The kidney has a unique distribution of sodium-dependent vitamin C transporters (SVCT1 and SVCT2). SVCT1 is situated in the brush-border membrane of proximal tubule cells where it is responsible for maintaining whole body ascorbate levels by mediating renal reabsorption, whereas SVCT2 is expressed basolaterally in all cells in the kidney except the proximal tubule ( 30 – 32 ). Both papillary and clear cell RCC are presumed to derive from the epithelium of the proximal tubule which only expresses SVCT1 ( 33 ).…”
Hypoxia-inducible transcription factors (HIFs) drive angiogenesis and cancer cell growth, contributing to an aggressive tumor phenotype. HIF-α protein levels and activity are controlled at the post-translational level by HIF hydroxylases. Hydroxylated HIF-α is recognized by the von Hippel Lindau (VHL) tumor suppressor and targeted for degradation. The HIF hydroxylases are members of the iron and 2-oxoglutarate-dependent dioxygenases, which require ascorbate as cofactor for activity. Clear cell renal cell carcinomas (ccRCC) harbor mutations in the VHL gene, whereas papillary RCC (pRCC) have a functional VHL. These natural occurring VHL variants in RCC enable the testing, in clinical samples, of the hypothesis that ascorbate modulates HIF-α levels through its role as a cofactor for the HIF hydroxylases. We measured ascorbate, HIF-1α, and HIF-2α protein and HIF downstream targets BNIP3, CA9, cyclin D1, GLUT1, and VEGF (combined to generate the HIF pathway score) in VHL-defective ccRCC (n = 73) and VHL-proficient pRCC human tumor tissue (n = 41). HIF and ascorbate levels were increased in ccRCC and pRCC tumors compared to matched renal cortex. HIF-1 and total HIF pathway activation scores were decreased with higher ascorbate in pRCC tumors (Spearman r = −0.38, p < 0.05 and r = −0.35, p < 0.05). This was not evident for ccRCC tumors. In mechanistic studies in vitro, ascorbate influenced HIF-1 activity in VHL-proficient, but not VHL-defective ccRCC cells. Our results indicate that ccRCC, which lacks a functional VHL, does not respond to ascorbate-mediated modulation of the HIF response. This contrasts with the demonstrated association between ascorbate content and the HIF pathway observed in pRCC and other tumors with a functional VHL. The results support a role for ascorbate as a modulator of HIF activity and tumor aggression in cancer types with a functional hypoxic response.
“…Because vitamin C is an anion at physiologic pH, it cannot simply diffuse across the cell membrane to extracellular fluid. Efflux transporters for the vitamin have not been identified (Eck et al , ). For intestinal epithelium and proximal renal tubular cells, vitamin C is absorbed by luminal transporters such as SVCT1.…”
Section: Ascorbic Acid and Dehydroascorbic Acid Transportmentioning
confidence: 99%
“…For rapid hormone‐dependent secretion of vitamin C to occur, a transport mechanism is likely to be responsible, but is as yet unidentified. Transport kinetics properties of SVCT1 and SVCT2 are ideal for transporting the vitamin into cells, but not for its secretion into plasma or extracellular fluids from cells (Eck et al , ).…”
Section: Ascorbic Acid and Dehydroascorbic Acid Transportmentioning
Vitamin C (Ascorbic Acid), the antiscorbutic vitamin, cannot be
synthesized by humans and other primates, and has to be obtained from diet.
Ascorbic acid is an electron donor and acts as a cofactor for fifteen mammalian
enzymes. Two sodium-dependent transporters are specific for ascorbic acid, and
its oxidation product dehydroascorbic acid is transported by glucose
transporters. Ascorbic acid is differentially accumulated by most tissues and
body fluids. Plasma and tissue vitamin C concentrations are dependent on amount
consumed, bioavailability, renal excretion, and utilization. To be biologically
meaningful or to be clinically relevant, in vitro and in vivo studies of vitamin
C actions have to take into account physiologic concentrations of the vitamin.
In this paper, we review vitamin C physiology; the many phenomena involving
vitamin C where new knowledge has accrued or where understanding remains
limited; raise questions about the vitamin that remain to be answered; and
explore lines of investigations that are likely to be fruitful.
“…Low plasma vitamin C is a risk factor for mortality and adverse cardiovascular events in hemodialysis patients [ 123 ], and AKI co-morbidities, such as diabetes, are associated with vitamin C deficiency [ 124 ]. The renal system is important in vitamin C re-absorption [ 125 ], and impairment may affect plasma ascorbate levels. Patients with renal dysfunction, such as septic, critically ill, and elderly, demonstrate low ascorbate levels [ 119 ], and bolstering vitamin C intake may prevent ROS-mediated renal damage in AKI.…”
Acute kidney injury causes significant morbidity and mortality in the community and clinic. Various pathologies, including renal and cardiovascular disease, traumatic injury/rhabdomyolysis, sepsis, and nephrotoxicity, that cause acute kidney injury (AKI), induce general or regional decreases in renal blood flow. The ensuing renal hypoxia and ischemia promotes the formation of reactive oxygen species (ROS) such as superoxide radical anions, peroxides, and hydroxyl radicals, that can oxidatively damage biomolecules and membranes, and affect organelle function and induce renal tubule cell injury, inflammation, and vascular dysfunction. Acute kidney injury is associated with increased oxidative damage, and various endogenous and synthetic antioxidants that mitigate source and derived oxidants are beneficial in cell-based and animal studies. However, the benefit of synthetic antioxidant supplementation in human acute kidney injury and renal disease remains to be realized. The endogenous low-molecular weight, non-proteinaceous antioxidant, ascorbate (vitamin C), is a promising therapeutic in human renal injury in critical illness and nephrotoxicity. Ascorbate may exert significant protection by reducing reactive oxygen species and renal oxidative damage via its antioxidant activity, and/or by its non-antioxidant functions in maintaining hydroxylase and monooxygenase enzymes, and endothelium and vascular function. Ascorbate supplementation may be particularly important in renal injury patients with low vitamin C status.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.